A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
12/2002
12/05/2002	US20020183379 Kits for determining risk of Alzheimer's disease
12/05/2002	US20020183378 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
12/05/2002	US20020183375 For therapy of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms
12/05/2002	US20020183369 For therapy of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis
12/05/2002	US20020183367 2,1-Oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
12/05/2002	US20020183365 Therapy or ameliorating an indication of the invention in an animal, including a human, comprising administering heteroaryl compond
12/05/2002	US20020183354 For therapy of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders
12/05/2002	US20020183353 For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse
12/05/2002	US20020183352 Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole
12/05/2002	US20020183351 For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse
12/05/2002	US20020183349 For therapy and prophylaxis of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes, sleep apnea
12/05/2002	US20020183345 Administering to a drug naive human patient in need of treatment, as first line therapy, a low dose of a combination of metformin and glyburide
12/05/2002	US20020183329 Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline
12/05/2002	US20020183323 For therpay of inflammatory bowel disease, cerebral ischemia and arthritis, adult respiratory distress syndrome (ARDS) and myocarditis, as adjuvants to short term immunosuppression in transplant therapy
12/05/2002	US20020183319 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer
12/05/2002	US20020183307 For therapy of hyperlipidemic condition
12/05/2002	US20020183305 For therapy of hyperlipidemic conditions such as are associated with atherosclerosis, hypercholesterolemia and other vascular conditions in mammals
12/05/2002	US20020183298 Pharmaceutical and food compositions containing" wood alcohols" or" wood sterols" useful for lowering serum cholesterol
12/05/2002	US20020183289 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
12/05/2002	US20020183288 Administering to a subject suffering from hyperparathyroidism an amount of active vitamin D formula sufficient to lower or maintain lowered blood parathyroid hormone (PTH) levels
12/05/2002	US20020183281 For therapy and prophylaxis of disorders that are ameliorated by the inhibition of neuronal monoamine uptake in mammals; disorders including erectile dysfunction, affective disorders, obesity, cerebral function disorders, pain
12/05/2002	US20020183269 Novel compounds
12/05/2002	US20020183263 Nutritional preparation comprising ribose and medical use thereof
12/05/2002	US20020183261 Oral administration of these can stimulate proliferation of osteoblast, inhibit bone resorption and strengthen bone; can be useful for improvement of osteoporosis, bone fracture, bone pain, etc
12/05/2002	US20020182728 Method for transdifferentiation of non pancreatic stem cells to the pancreatic differentiation pathway
12/05/2002	US20020182683 Vascular endothelial growth factor 2
12/05/2002	US20020182681 Peptide for use in treatment of cancer, parkinson's and metabolic disorders
12/05/2002	US20020182612 Diagnosing inflammatory defects in humans; obtain nucleotide sequence sample, incubate with probe associated with preferential allele, detect hybridization, hybridization indicates sensitivty to inflammatory defect
12/05/2002	US20020182276 Morinda citrifolia (Noni) enhanced animal food product
12/05/2002	US20020182269 Cucumis melo extract coated and/or microencapsulated in a fat-soluble agent based on a fatty substance
12/05/2002	US20020182266 Vitamin C, vitamin E, beta-carotene, zinc and copper, preferably in tablet form
12/05/2002	US20020182210 Treatment of central nervous system diseases by antibodies against glatiramer acetate
12/05/2002	US20020182208 Glycosylated antibody
12/05/2002	US20020182182 Recombinant viral vector encoding a human very low density lipoprotein (VLDL) receptor, operatively linked to regulatory sequences directing expression in a hepatocyte; familial hypercholesterolemia or hyperlipidemia
12/05/2002	US20020182181 Generated from a bacteriophage; gene expression inhibition
12/05/2002	US20020182168 Administering to a patient a therapeutically effective amount of an amine polymer, wherein the amine polymer is water insoluble or nonabsorbent in the gastrointestinal tract to treat the copper toxicosis and Wilson's disease
12/05/2002	DE10126434A1 New tricyclic thiochromenone derivatives as metabotropic glutamate receptor-1 (mGluR1) antagonists useful for treating e.g. hemorrhagic stroke and atherosclerosis, especially pain or neurodegenerative diseases
12/05/2002	CA2459176A1 Oral composition comprising an extract from the bark of albizzia myriophylla
12/05/2002	CA2452154A1 Carbohydrate modifying agent and drinks containing the modifying agent
12/05/2002	CA2451838A1 Stem cell differentiation
12/05/2002	CA2449199A1 Coenzyme q and eicosapentaenoic acid (epa)
12/05/2002	CA2449160A1 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	CA2449006A1 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
12/05/2002	CA2449004A1 Melanin-concentrating hormone analogs
12/05/2002	CA2448953A1 Assay for beta cell toxic macrolides
12/05/2002	CA2448645A1 New phenylalkyloxy-phenyl derivatives
12/05/2002	CA2448643A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a biguanide drug
12/05/2002	CA2448639A1 Novel heterocyclic derivatives and medicinal use thereof
12/05/2002	CA2448637A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin
12/05/2002	CA2448626A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	CA2448567A1 Modulators of nucleic acid ligands
12/05/2002	CA2448362A1 B7 related protein-2 molecules and uses thereof
12/05/2002	CA2448348A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
12/05/2002	CA2448320A1 Ribozyme based treatment of female reproductive diseases
12/05/2002	CA2448306A1 Method for treating fibrotic diseases or other indications
12/05/2002	CA2448294A1 Method for treating fibrotic diseases or other indications vi
12/05/2002	CA2448248A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	CA2448205A1 Oxazol/thiazol-derivatives activators of the hppar-alpha receptor
12/05/2002	CA2448148A1 Carbohydrate-associated proteins
12/05/2002	CA2448109A1 Alternative splice forms of proteins as basis for multiple therapeutic modalities
12/05/2002	CA2448103A1 Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
12/05/2002	CA2448101A1 Process for preparing a thialzole ppar-ligand and polymorphs thereof
12/05/2002	CA2448062A1 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	CA2448023A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002	CA2447879A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	CA2447662A1 Transporters and ion channels
12/05/2002	CA2447475A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	CA2443713A1 Proteins associated with cell growth, differentiation, and death
12/05/2002	CA2411907A1 Preparation with vascular protective and anti-oxidative effect and use thereof
12/05/2002	CA2411549A1 Ligands of integrin receptors
12/05/2002	CA2411082A1 Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament
12/04/2002	EP1262546A1 Novel scavenger receptors
12/04/2002	EP1262543A1 Alpha-amylase activity inhibitors
12/04/2002	EP1262541A1 Production of bioavailable folic acid
12/04/2002	EP1262189A1 Leptin-resistance ameliorating agents
12/04/2002	EP1262187A1 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
12/04/2002	EP1262183A1 Use of norastemizole for the treatment of allergic rhinitis
12/04/2002	EP1262178A2 Suppressor of anemia and appetite suppressor comprising threonine alone or in combination with methionine
12/04/2002	EP1262173A1 Oral intake solution comprising reduced water
12/04/2002	EP1261736A2 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides
12/04/2002	EP1261712A2 Proteins named fctrx and nucleic acids encoding same
12/04/2002	EP1261700A2 Cis acting regulatory nucleic acid sequences in the parathyroid hormone 3'-untranslated region
12/04/2002	EP1261636A2 Human protein kinases and protein kinase-like enzymes
12/04/2002	EP1261625A2 Memno peptides, a process for their preparation and their use
12/04/2002	EP1261605A1 Benzoxazole derivatives as tnf and pde iv inhibitors
12/04/2002	EP1261604A1 Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them
12/04/2002	EP1261601A1 Substituted indoles for modulating nfkb activity
12/04/2002	EP1261594A1 5,10-dihydroacridines as calcium channel blockers
12/04/2002	EP1261593A1 8,8a-dihydro-indeno 1,2-d]thiazole derivatives with a sulphonamido or sulphono substituent in the 2 position, a method for production thereof and use thereof as a medicament
12/04/2002	EP1261590A1 Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
12/04/2002	EP1261588A1 New imidazole derivatives
12/04/2002	EP1261586A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv, processes for their preparation, and their use
12/04/2002	EP1261585A1 Substituted indole mannich bases
12/04/2002	EP1261427A2 Microfabricated devices and methods for storage and selective exposure of chemicals
12/04/2002	EP1261373A2 Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions
12/04/2002	EP1261368A2 Lipase-containing composition and methods of use thereof
12/04/2002	EP1261360A1 Casein derived peptides and uses thereof in therapy
12/04/2002	EP1261330A2 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and in lower animals
12/04/2002	EP1261320A2 Micellar pharmaceutical compositions for buccal and pulmonary application
12/04/2002	EP1097139B1 Quinoline derivatives

1 ... 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 ... 1298